NuVasive — Q1 2016 Earnings Presentation
12 slides from NuVasive's earnings presentation, Apr 26, 2016
Slide 1: NuVasive, Inc. First Quarter 2016 Results
Exhibit 99.2 NuVasive, Inc. First Quarter 2016 Results April 26, 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements NuVasivecautionsyou that statementsincludedin this presentationthat are not a descriptionof historical factsare forward-lookingstatementsthat involverisks,uncertainties,assumptionsand other factorswhich, if they do not materializeor provecorrect,couldcauseNuVasive’sresults
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures Managementusescertain non-GAAPfinancial measuressuchas non-GAAPearningsper share,non-GAAP net income, non-GAAPoperating expenses and non-GAAPoperating profit margin, which exclude amortization of intangible assets, purchase accounting related charges, leasehold related ch
Slide 4: First Quarter 2016 Performance Highlights
First Quarter 2016 Performance Highlights Double-digit revenue growth and profitability expansion Innovation Growth Profitability • Completed acquisition of Ellipse • Returned to double-digit • Delivered 150 basis points of Technologies and now focused revenue growth up 12.3%, profitability expansio
Slide 5: NuVasive's Formula for Success
NuVasive’sFormulaforSuccess Fueling 2016 strategic agenda with proven approach to win Industry disruptor Driving organic growth adding value and with numerous inorganic addressing unmet needs opportunities available Profitability Operational excellence delivering significant margin expansion 5 ©2016
Slide 6: First Quarter 2016 Revenue Highlights
First Quarter 2016 Revenue Highlights Strong revenue performance in key growth areas U.S. SPINAL HARDWARE U.S. SURGICAL SUPPORTINTERNATIONAL Includes All Implants, Fixation, MAGEC® Includes Biologics, IOM Services Includes Puerto Rico & PRECICE® & Disposables Up 15.0% in 1Q16 Up 3.7% in 1Q16 Up 20.7
Slide 7: Driving Improved Financial Profile
Driving Improved Financial Profile Improve Adjusted EBITDA, reduce tax rate and lower depreciation Increased Focus on Driving Improved Reducing Non-GAAP Adjusted EBITDA Through Disciplined Effective Tax Rate* Spending and Improved Efficiencies Driving to ~41% in 2016 Mid to High 30% in 2017 Adjusted
Slide 8: NuVasive Specialized Orthopedics (NSO)
NuVasive Specialized Orthopedics™ (NSO) Ellipse Technologies Integrates Into Newly Created NUVA Division 1Q16 1Q16 YoYGrowth Actuals NSO Revenues • As Reported –February 12 to March 31, 2016 $5.8M N/A • ProForma –January 1 to March 31, 2016 $11.7M 39.3% NUVACore Revenues • U.S. $182.7M 8.9% • Intern
Slide 9: First Quarter 2016 P&L Performance
First Quarter 2016 P&L Performance Operating leverage story continues to play out 1Q16 1Q16 YoY Actuals Performance Factors Non-GAAP Measures 80 bps drivenby asset efficiencies, Gross Margin 77.1% lower royalties, med device tax repeal 80 bps driven by asset efficiencies, Sales, Marketing & Admin. 5
Slide 10: Completed 2021 Convertible Notes Issuance
Completed 2021 Convertible Notes Issuance Provides certainty, extends maturities and addresses potential dilution • Raised $650 million, including a $100 million over-allotment option, generating net proceeds of ~$634 million • Notes have a coupon rate of 2.25%, in addition to callable feature that
Slide 11: Full Year 2016 Financial Performance Guidance
Full Year 2016 Financial Performance Guidance* Reflects Impact of Acquisitions, Convertible Note Issuance and Note Repurchases, and Expected Currency Rates FY16 Guidance Performance Drivers Revenues • As reported ~$928.0M, ~14%YoYgrowth^ ~$53M NSO contribution; ~$5M currency impact • Full yearpro fo
Slide 12: Why Invest in NuVasive
Why Invest in NuVasive Relentless focus on driving shareholder value Competitively positioned in large and growing global spine market with favorable transformative dynamics playing to NuVasive strengths Industry-leading innovation and Drive surgeon conversion, Double International revenue integrate